tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
PremiumRatingsHold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
2M ago
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
Premium
Company Announcements
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
2M ago
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
Premium
Ratings
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
2M ago
RBC downgrades Jasper Therapeutics on questions about briquilimab
PremiumThe FlyRBC downgrades Jasper Therapeutics on questions about briquilimab
3M ago
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
Premium
The Fly
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
3M ago
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
3M ago
Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile
PremiumRatingsBuy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile
3M ago
Jasper Therapeutics price target lowered to $20 from $64 at BTIG
Premium
The Fly
Jasper Therapeutics price target lowered to $20 from $64 at BTIG
3M ago
Jasper Therapeutics downgraded to Market Perform at William Blair
Premium
The Fly
Jasper Therapeutics downgraded to Market Perform at William Blair
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100